Budecort RespuIes o.5 mg

Budecort 0.5mg Respules (Budesonide): Complete Medical Guide — Uses, Dosage, Side Effects & Precautions 

Critical Correction — Age of Use: One reviewed source document (365.docx) states this medication “is not prescribed to anyone younger than 18 years old.” This is directly contrary to the FDA-approved label and to the actual primary purpose of this specific formulation .Budecort/Pulmicort Respules is specifically FDA-approved for the maintenance treatment of asthma in children 12 months to 8 years of age — infants and young children are, in fact, the primary intended population for this nebulised formulation, precisely because they cannot use inhaler devices. This is correctly and extensively detailed by allday.docx, which accurately describes use “from 6 months of age” in some clinical contexts. The claim in 365.docx appears to have been written for, or copied from, a different Budesonide product (such as an adult-only formulation) and is inaccurate and potentially harmful if it discouraged appropriate use in an infant or young child for whom this medication is specifically indicated and evidence-supported.

Critical Correction — Crohn’s Disease and Ulcerative Colitis: 365.docx lists “Crohn’s Disease” and “Ulcerative Colitis” as uses for this product, immediately after describing “Budecort Respules 0.5mg” specifically. This is misleading as presented. Oral, controlled-release Budesonide formulations (branded as Entocort EC or Uceris in the United States) are indeed FDA-approved for mild-to-moderate Crohn’s disease affecting the ileum and ascending colon, and for ulcerative colitis — but these are entirely different oral capsule/tablet formulations designed for gut-targeted release, not the nebuliser suspension described throughout the rest of this same document. Nebulised Budecort Respules 0.5mg is not used for Crohn’s disease or ulcerative colitis — it is a respiratory (asthma) treatment. Presenting these together, without distinguishing the formulations, risks a patient believing their asthma nebuliser solution treats an unrelated gastrointestinal condition, or vice versa. 

Recurring Factual Errors (also found in the 1mg strength of this product): cheap.docx again describes the mechanism as “decreases the activity of acetylcholine in the lung” — this describes an anticholinergic bronchodilator, not a corticosteroid, and is incorrect (see the accurate mechanism explained below). The same document also repeats the claim that “Respules may explode at high temperatures” near a flame — an unsupported claim; Respules are sealed plastic ampoules of liquid suspension, not pressurised canisters. cheap.docx also again lists glaucoma and cystic fibrosis as absolute conditions to “avoid,” when these actually warrant monitoring/caution rather than automatic exclusion. 

 

Regulatory Note: Budecort 0.5mg Respules contains Budesonide 0.5mg in a 2mL sterile suspension for nebulisation, manufactured by Cipla Ltd., India. The originator branded product, Pulmicort Respules (AstraZeneca), received FDA approval in 2000 and is specifically indicated for children 12 months to 8 years of age as its primary paediatric population, alongside broader use in patients unable to use inhaler devices. 

What is Budecort 0.5mg Respules? 

Budecort 0.5mg Respules is a sterile, preservative-free suspension of micronised Budesonide at 0.25mg/mL concentration (0.5mg total per 2mL respule), designed for administration via a jet nebulizer — correctly, ultrasonic nebulizers are not suitable and are not recommended for this medication. It is the lower of the two standard adult/paediatric strengths (alongside 1mg), and a 0.25mg strength also exists for the lowest paediatric starting doses. 

This is the standard low-to-medium dose ICS formulation for young children who cannot effectively use a metered-dose inhaler, even with a spacer and mask, due to age, distress, or inability to coordinate breathing with the device — correctly and thoroughly explained by allday.docx. 

How Does Budecort 0.5mg Respules Actually Work? 

Mechanism of Action — Corticosteroid, Not Bronchodilator 

Budesonide belongs to the glucocorticoid class of corticosteroids — 365.docx describes this correctly and in genuinely useful detail: it works by inhibiting the release of multiple inflammatory cell types (mast cells, eosinophils, neutrophils, macrophages, and lymphocytes) and inflammatory mediators (histamine, eicosanoids, leukotrienes, and cytokines) that drive airway inflammation. This is a genuinely accurate and more detailed mechanism description than found in the other two source documents for this drug pair. 

This action reduces airway swelling and mucus production over weeks to months of regular use — it is a preventive, anti-inflammatory treatment, not a fast-acting bronchodilator. This distinction is important because cheap.docx’s acetylcholine-based description (repeated from the 1mg version of this product) is simply incorrect and describes a different drug class entirely. 

Uses of Budecort 0.5mg Respules 

Primary Indication: Asthma Maintenance in Young Children 

Budecort 0.5mg Respules is FDA-referenced (via the Pulmicort Respules reference product) for the maintenance treatment of asthma and as prophylactic therapy specifically in children 12 months to 8 years of age, with allday.docx providing an accurate and detailed account of this population and clinical rationale — the nebulised route removes the need for breath coordination or spacer/mask tolerance that limits inhaler use in this age group. 

Other Age Groups and Settings 

It is also used in older children and adults who cannot effectively use inhaler devices — due to severe breathlessness during exacerbations, disability, or in hospital and home nebulisation settings for asthma management. 

Off-Label Use: Eosinophilic Esophagitis 

Nebulised Budesonide (typically swallowed rather than inhaled in this specific off-label application) has been used for eosinophilic esophagitis (EoE), a chronic immune/allergic condition of the esophagus — an entirely different, genuine off-label GI-related use, distinct from the Crohn’s/ulcerative colitis confusion in 365.docx. This specific off-label EoE use is not mentioned in any of the three source documents. 

Dosage and Administration 

The FDA-referenced starting dose framework depends on prior asthma therapy: 

• Children not previously on inhaled corticosteroids, or previously on bronchodilators alone: starting dose as low as 0.25mg once daily may be considered 
• Standard starting/maintenance dose for many children: 0.5mg once daily (this strength) 
• If once-daily dosing does not achieve adequate control: total daily dose may be increased and/or given as a divided (twice-daily) dose 
• Once asthma stability is achieved: the dose should be titrated down to the lowest effective maintenance level 
• Nebuliser/compressor system: the pivotal U.S. clinical trials specifically used a Pari-LC-Jet Plus Nebulizer with a Pari Master compressor — the FDA label notes safety and efficacy with other nebulizer/compressor combinations have not been separately established, so using a comparable, appropriate jet system as directed by your prescriber or pharmacist is advisable 

How to Take Budecort 0.5mg Respules 

• Use only with a jet nebulizer connected to an air compressor 
• Gently shake the respule using a circular motion before opening, per FDA labeling instructions — a small but genuine practical detail missing from all three source documents 
• Twist off the top and empty the entire 2mL contents into the nebuliser chamber 
• For young children: use a properly fitting face mask covering both nose and mouth, keeping the child as calm and still as possible — correctly and helpfully detailed by allday.docx 
• Do not mix with other nebulisable medications unless specifically directed by your prescriber — the FDA label notes this has not been adequately assessed 
• After nebulisation, rinse the mouth and spit, and wash the face if a mask was used 
• Discard any unused portion of an opened respule immediately 

Missed Dose 

Take the missed dose as soon as remembered; do not double the dose to compensate. 

Overdose 

Seek emergency medical attention or contact your doctor if an overdose is suspected. 

Two Important Clinical Points Correctly Covered Only by allday.docx 

Oral Corticosteroid Tapering 

allday.docx correctly and importantly notes: patients transferring from oral (systemic) corticosteroids to nebulised Budesonide require gradual oral steroid tapering, because nebulised Budesonide alone does not provide sufficient systemic corticosteroid activity to compensate for abruptly withdrawn systemic steroids. The FDA label reinforces this, noting that patients previously on 20mg or more per day of prednisone (or its equivalent) may be most susceptible to problems during this transition, and should be carefully monitored for signs of adrenal insufficiency (fatigue, weakness, nausea) alongside their lung function and asthma symptoms during the taper. Neither cheap.docx nor 365.docx mentions this important transition safety point at all. 

Growth Monitoring in Children 

allday.docx correctly notes that growth monitoring is standard practice for children on long-term ICS therapy. A specific pivotal FDA trial in 141 children aged 6 to 12 months with mild-to-moderate asthma, comparing 0.5mg, 1mg, and placebo doses over 12 weeks, specifically measured growth velocity effects as part of establishing this medication’s paediatric safety profile — reinforcing that this is a genuinely studied and monitored consideration, not a theoretical concern. 

Side Effects of Budecort 0.5mg Respules 

Common Side Effects 

• Cough during or shortly after nebulisation 
• Mild throat irritation, hoarseness of voice 
• Stuffy or runny nose, sneezing 
• Fever (correctly listed by both cheap.docx and 365.docx — likely reflecting the higher background rate of respiratory infections in the treated paediatric population rather than a direct drug effect) 
• Abdominal pain, diarrhoea 

A Genuine Advantage of the Nebulised Route — Lower Thrush Risk 

allday.docx makes a genuinely useful and accurate clinical point missing from the other two sources: oropharyngeal candidiasis (oral thrush) is less frequent with nebulised Budesonide than with pMDI (inhaler) administration, because a higher proportion of the nebulised dose reaches the lower airways rather than depositing in the mouth and throat. Rinsing the mouth after use remains good practice regardless. 

Serious Side Effects — Seek Immediate Medical Attention 

• Signs of adrenal insufficiency during oral steroid taper: fatigue, weakness, nausea — see dedicated section above. 
• Pneumonia: the FDA pivotal paediatric trial data noted pneumonia was observed somewhat more frequently in children treated with Pulmicort Respules than placebo — a specific finding not mentioned in any of the three source documents, worth being aware of, particularly in young children with recurrent respiratory symptoms. 
• Vision changes: rare instances of glaucoma, increased intraocular pressure, and cataracts have been reported with inhaled budesonide — correctly flagged as a symptom to watch for by cheap.docx, though incorrectly framed there as an absolute contraindication for existing glaucoma rather than a monitoring consideration. 
• Severe allergic reactions or bronchospasm: facial swelling, rash, hives, or sudden worsening of breathing require emergency treatment. 

Precautions and Warnings 

Active Tuberculosis and Respiratory Infections 

This medication should not be used in patients with active pulmonary tuberculosis, and should be used with caution in patients with bacterial, fungal, or viral respiratory infections, as correctly detailed by allday.docx — the immunosuppressive local effect may worsen these infections without appropriate concurrent antimicrobial therapy. 

Glaucoma and Cystic Fibrosis —  Correcting cheap.docx’s Overstated Contraindications 

As with the 1mg strength, cheap.docx incorrectly lists glaucoma and cystic fibrosis as absolute conditions requiring avoidance. Glaucoma warrants monitoring during long-term ICS use, not automatic exclusion; cystic fibrosis is not a standard contraindication for nebulised Budesonide. 

Bone Density 

Long-term, high-dose inhaled corticosteroid use has been associated with reduced bone mineral density in some patients — a legitimate long-term consideration correctly noted by cheap.docx. 

Liver Disease 

Use with caution in hepatic impairment, given budesonide’s reliance on hepatic CYP3A4 metabolism for clearance. 

Pregnancy and Breastfeeding 

A large Swedish population-based registry study covering approximately 99% of pregnancies from 1995–1997 found no increased risk of congenital malformations associated with inhaled budesonide in early pregnancy — more specific and reassuring evidence than the generic “use with caution” guidance in all three source documents. Budesonide’s presence in human breast milk has not been definitively established, though caution is advised given other corticosteroids are known to be excreted in breast milk. 

Driving and Machinery 

This medication has no or negligible influence on the ability to drive or operate machinery — correctly noted by 365.docx. 

 Storage Instructions 

• Store unopened respules protected from light, at room temperature below 30°C
• Do not freeze 
• There is no genuine explosion risk from heat exposure — see correction above — but avoiding excessive heat and direct sunlight remains sensible for product stability 
• Never store an opened respule for later use — discard any unused portion immediately 
• Keep out of reach of children 

Frequently Asked Questions (FAQs) 

Can infants and young children use Budecort 0.5mg Respules? 

Yes — this is one of its primary intended uses. This medication is specifically FDA-referenced for the maintenance treatment of asthma in children 12 months to 8 years of age, precisely because nebulisation does not require the breath coordination needed for inhaler devices. A claim that this medication is unsuitable for anyone under 18 is inaccurate. 

Does Budecort 0.5mg Respules treat Crohn’s disease or ulcerative colitis? 

No — this specific nebulised suspension does not. A different oral formulation of Budesonide (branded Entocort EC or Uceris in the US) is FDA-approved for these gastrointestinal conditions, but that is an entirely separate product designed for gut-targeted release, not the respiratory nebuliser solution described in this guide. 

Is Budecort 0.5mg Respules a bronchodilator? 

No. It is an inhaled corticosteroid, working through an anti-inflammatory glucocorticoid receptor mechanism — not through effects on acetylcholine, and not through the rapid airway muscle relaxation that defines true bronchodilators like salbutamol. 

Why is oral steroid tapering important when starting this medication? 

If switching from oral/systemic corticosteroids, the dose must be tapered gradually rather than stopped abruptly, because nebulised Budesonide alone does not provide enough systemic corticosteroid activity to prevent adrenal insufficiency from sudden systemic steroid withdrawal. This transition should always be managed and monitored by your prescriber. 

Is oral thrush more or less common with nebulised Budesonide compared to an inhaler? 

Generally less common with nebulisation, since a higher proportion of the dose reaches the lower airways rather than depositing in the mouth and throat — though rinsing the mouth after each use is still good practice. 

Medical Disclaimer 

All information in this guide is provided for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Budecort 0.5mg Respules is a prescription-only medication and should only be used under the supervision of a licensed healthcare provider, with the specific jet nebuliser device type recommended. Never self-medicate or adjust the dose without medical guidance. In an emergency, contact local emergency services immediately. Report suspected adverse effects to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.